Literature DB >> 30557043

Prostate transmembrane protein androgen induced 1 is induced by activation of osteoclasts and regulates bone resorption.

Xianghe Xu1,2, Hirohito Hirata1, Makoto Shiraki1, Asana Kamohara1, Kenichi Nishioka3, Hiroshi Miyamoto1, Toshio Kukita2, Akiko Kukita1.   

Abstract

Osteoclasts derived from hematopoietic cells are activated on bone surface. To resorb bone, osteoclasts release acid and lysosome acid hydrolase via membrane transport. Prostate transmembrane protein androgen induced 1 (Pmepa1) is a type I transmembrane protein that regulates proliferation, migration, and metastasis of cancer cells. Because recent reports showed that Pmepa1 is involved in membrane transport in cancer cells, we investigated the role of Pmepa1 in osteoclast function. Pmepa1 expression was barely detected in osteoclasts formed on plastic surfaces in vitro, but was markedly increased in activated osteoclasts formed on calcified matrix. Inhibitors of bone resorption, such as alendronate, bafilomycin A1, and the PI3K inhibitor LY294002, suppressed the expression of Pmepa1 in osteoclasts. Knockdown of Pmepa1 expression impaired bone resorption activity and inhibited formation of a ring-like, actin-rich podosome belt that is essential for osteoclast function. Pmepa1 protein localized to lysosomes in osteoclasts. In addition, in sites of bone destruction observed in rats with adjuvant-induced arthritis, a marked high level of Pmepa1 expression was associated with the osteoclasts' resorbing bone. Our results suggest that Pmepa1 is a critical regulator of bone resorption and is a promising marker for activated osteoclasts and a potential therapeutic target in pathologic bone destruction.-Xu, X., Hirata, H., Shiraki, M., Kamohara, A., Nishioka, K., Miyamoto, H., Kukita, T., Kukita, A. Prostate transmembrane protein androgen induced 1 is induced by activation of osteoclasts and regulates bone resorption.

Entities:  

Keywords:  Nedd4; TGF-β; arthritis; lysosome; membrane trafficking

Year:  2018        PMID: 30557043     DOI: 10.1096/fj.201801573R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  4 in total

1.  Study on the cellular internalization mechanisms and in vivo anti-bone metastasis prostate cancer efficiency of the peptide T7-modified polypeptide nanoparticles.

Authors:  Yongwei Gu; Xinmei Chen; Haiyan Zhang; Heyi Wang; Hang Chen; Sifan Huang; Youfa Xu; Yuansheng Zhang; Xin Wu; Jianming Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 2.  Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.

Authors:  Daniel E Hagaman; Jossana A Damasco; Joy Vanessa D Perez; Raniv D Rojo; Marites P Melancon
Journal:  Molecules       Date:  2021-01-13       Impact factor: 4.411

3.  Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1.

Authors:  David H H Molstad; Elizabeth Zars; Andrew Norton; Kim C Mansky; Jennifer J Westendorf; Elizabeth W Bradley
Journal:  Sci Rep       Date:  2020-12-11       Impact factor: 4.379

4.  Overexpression of c-Fos reverses osteoprotegerin-mediated suppression of osteoclastogenesis by increasing the Beclin1-induced autophagy.

Authors:  Xishuai Tong; Miaomiao Chen; Ruilong Song; Hongyan Zhao; Jianchun Bian; Jianhong Gu; Zongping Liu
Journal:  J Cell Mol Med       Date:  2020-12-04       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.